Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 11-12, 2010, Pages 1323-1331

  Chan, H L Y ^a   Wong, V W S ^a   Chim, A M L ^a   Chan, H Y ^a   Wong, G L H ^a   Sung, J J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78449281983     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04474.x     Document Type: Article

References (34)

1. Chan HL, Sung JJ,. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153 - 61.
2. Sung JJ, Tsoi KK, Li KC, Wong VW, Chan HL,. Meta-analysis: treatment of hepatitis B infection reduces risk of hepato-cellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067 - 77.
3. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298 - 305.
4. Chan HL, Hui Y, Wong VW, Chim AM, Wong ML, Sung JJ,. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41: 1357 - 64.
5. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169 - 79.
6. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b. Gastroenterology 2008; 135: 459 - 67.
7. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen positive chronic hepatitis B. Hepatology 2010; 51: 1945 - 53.
8. Hui AY, Chan HL, Cheung A, Cooksley G, Sung JJ,. Treatment of chronic hepatitis B virus infection by pegylated interferon: systematic review of 4 randomized studies. Aliment Pharmacol Ther 2005; 22: 519 - 28.
9. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002 - 9.
10. Wong GL, Chan HL,. Molecular virology in chronic hepatitis B: genotypes. Hosp Med 2005; 66: 13 - 6.
11. Wong GL, Chan HL,. Predictors of treatment response in chronic hepatitis B. Drug 2009; 69: 2167 - 77.
12. Zhu YY, Dong J, Chan YT, Chen J, Jiang JJ,. Extending the treatment duration of peginterferon alfa-2a therapy to 72 weeks increases the rate of HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50 (Suppl. 1): S331 - 2.
13. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750 - 8.
14. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462 - 8.
15. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151 - 7.
16. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141 - 50.
17. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240 - 50.
18. Chan HL, Wong VW, Chim AM, et al. Virological response to different combination regimes of peginterferon alfa-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antiviral Ther 2007; 12: 815 - 23.
19. Chan HL, Wong WS, Chim AM, Wong GL, Chan HY, Sung JJ,. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). Antivir Ther 2008; 13: 555 - 62.
20. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217 - 22.
21. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182 - 7.
22. Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406 - 12.
23. European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227 - 42.
24. Liaw YF, Leung NW, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263 - 83.
25. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507 - 39.
26. Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sung JJ,. Early hepatitis B virus DNA suppression can predict virological response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008; 6: 1022 - 6.
27. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428 - 34.
28. Ter Borg MJ, Van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44: 721 - 7.
29. Lau GK, Marcellin P, Brunetto M, et al. On-treatment HBsAg decline during peginterferon alfa-2a (40 kD) ± lamivudine in patients with HBsAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology 2008; 48 (Suppl.): 714A.
30. Lau GK, Marcellin P, Brunetto M, et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50 (Suppl. 1): S333.
31. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ,. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010 [Epub ahead of print].
32. Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 123 - 9.
33. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682 - 95.
34. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA. Hepatology 2010; 52: 765 - 73.